Header Skipped.
Heart valve disease management represents an unmet clinical need. Studies have shown that valve disease has an increasing incidence with age, dramatically spiking after age 65.
There is an overall prevalence of 2.5% for any valve disease. Bicuspid aortic valve disorder is the most common cardiovascular defect. Patients who have valve disease have a 79% survival rate at five years and 68% at eight years following diagnosis. Patients without valve disease have a 93% survival rate and 86% survival rate and five and eight years, respectively.
The Heart Valve Translational Research Program (HVTRP) at Brigham and Women’s Hospital (BWH) was developed to find treatments to cure heart valve diseases through innovative, multidisciplinary research.
To address the complexities of valve diseases and expedite new treatment options, we have assembled a multidisciplinary team from departments throughout BWH. The team approach allows us to:
The goals of the Heart Valve Translational Research Program are to:
Leadership
Program Director, Heart Valve Translational Research Program Cardiovascular Medicine
Clinical Co-Director
Chief, Cardiovascular Medicine
Advisory Board
Pathology
Cardiovascular Medicine
Chief, Cardiac Surgery
Cardiovascular Medicine Team
Cardiovascular Medicine; Director, Center for Interdisciplinary Cardiovascular Sciences
Director, Cardiovascular Genetic Center
Cardiovascular Medicine
Multidisciplinary Team
Anesthesia and Pain Management
Executive Medical Director, Cardiovascular Imaging Program
Professor, Harvard-MIT's Division of Health Sciences and Technology
Senior Pathologist and Professor of Pathology, Health Sciences and Technology, Harvard Med. School
Search our A to Z guide to locate general information about heart and vascular diseases, conditions, treatments, and clinical programs at Brigham and Women's Hospital.
For over a century, a leader in patient care, medical education and research, with expertise in virtually every specialty of medicine and surgery.
About BWH